Anthem Biosciences IPO Allotment Date is Today; Shares to Be Credited on July 18

Anthem Biosciences IPO, one of the anticipated upcoming IPOs, opened for subscription on July 14, 2025, and closed on July 16, 2025. 

Anthem Biosciences IPO Allotment Status and Listing Details

The company is expected to finalise the share allotments today, Thursday, July 17, 2025. Successful bidders can expect the shares to be credited to their demat accounts on Friday, July 18, 2025. 

Those who did not receive an allotment will likely receive refunds on the same day. You can check the IPO allotment status on the NSE or BSE websites or visit the official registrar's website. Kfin Technologies Limited is the registrar for the issue.

The Anthem Biosciences share is expected to be listed on the NSE and BSE on Monday, July 21, 2025.

Anthem Biosciences IPO Structure and Offer Size

This IPO was a bookbuilding issue amounting to ₹3,395.00 crores. The issue is entirely an offer for sale of 5.96 crore shares.

The price band for the Anthem Biosciences IPO was set at ₹570 per share, with a minimum application lot size of 26 shares, requiring retail investors to invest at least ₹14,040. 

Subscription Status

On Day 3, July 16, 2025, the Anthem Biosciences IPO subscribed 67.42 times. The public issue was subscribed 5.98 times in the retail category, 192.80 times in the Qualified Institutional Buyers (QIB) category, and 44.70 times in the Non-Institutional Investors (NII) category.

Also Read: Upcoming IPOs This Week: 1 Mainboard and 2 SME IPOs Set to Open This Week Starting from July 14!

Conclusion

Anthem Biosciences IPO saw demand, especially from institutional investors, with an overall subscription of 67.42 times. The allotment is expected to be finalised on July 17, 2025, and listing is scheduled for July 21, 2025. Investors are now keenly awaiting listing gains.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.